Comparative Pharmacology
Head-to-head clinical analysis: CONRAY 43 versus OSMOVIST 240.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY 43 versus OSMOVIST 240.
CONRAY 43 vs OSMOVIST 240
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during imaging.
Nonionic iodinated contrast medium that attenuates X-rays is excreted unchanged in urine; increases density of blood vessels and tissues to enhance radiological visualization.
Intravenous: 0.5-1.0 mL/kg (20-43 mg I/kg) for CT; intra-arterial: 5-15 mL for selective studies; maximum single dose 150 mL.
Intravenous bolus injection: 0.5 mL/kg to 1 mL/kg of Osnovist 240 (240 mg iodine/mL) for CT enhancement, up to a maximum of 150 mL per dose.
None Documented
None Documented
2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life approximately 2 hours (range 1.5–4 hours) in patients with normal renal function; prolonged in renal impairment proportional to creatinine clearance.
Renal: >90% via glomerular filtration; unchanged drug. Biliary: <1%. Fecal: negligible.
Primarily renal (glomerular filtration); >95% of administered dose excreted unchanged in urine within 24 hours. Negligible biliary/fecal elimination (<5%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent